271 related articles for article (PubMed ID: 21171987)
1. qPCR in gastrointestinal stromal tumors: Evaluation of reference genes and expression analysis of KIT and the alternative receptor tyrosine kinases FLT3, CSF1-R, PDGFRB, MET and AXL.
Fassunke J; Blum MC; Schildhaus HU; Zapatka M; Brors B; Künstlinger H; Büttner R; Wardelmann E; Merkelbach-Bruse S
BMC Mol Biol; 2010 Dec; 11():100. PubMed ID: 21171987
[TBL] [Abstract][Full Text] [Related]
2. A novel tyrosine kinase switch is a mechanism of imatinib resistance in gastrointestinal stromal tumors.
Mahadevan D; Cooke L; Riley C; Swart R; Simons B; Della Croce K; Wisner L; Iorio M; Shakalya K; Garewal H; Nagle R; Bearss D
Oncogene; 2007 Jun; 26(27):3909-19. PubMed ID: 17325667
[TBL] [Abstract][Full Text] [Related]
3. Novel receptor tyrosine kinase targeted combination therapies for imatinib-resistant gastrointestinal stromal tumors (GIST).
Mahadevan D; Theiss N; Morales C; Stejskal AE; Cooke LS; Zhu M; Kurtzman D; Swart R; Ong E; Qi W
Oncotarget; 2015 Feb; 6(4):1954-66. PubMed ID: 25557174
[TBL] [Abstract][Full Text] [Related]
4. Activated tyrosine kinases in gastrointestinal stromal tumor with loss of KIT oncoprotein expression.
Tu Y; Zuo R; Ni N; Eilers G; Wu D; Pei Y; Nie Z; Wu Y; Wu Y; Ou WB
Cell Cycle; 2018; 17(23):2577-2592. PubMed ID: 30488756
[TBL] [Abstract][Full Text] [Related]
5. Platelet-Derived Growth Factor Receptor-α Regulates Proliferation of Gastrointestinal Stromal Tumor Cells With Mutations in KIT by Stabilizing ETV1.
Hayashi Y; Bardsley MR; Toyomasu Y; Milosavljevic S; Gajdos GB; Choi KM; Reid-Lombardo KM; Kendrick ML; Bingener-Casey J; Tang CM; Sicklick JK; Gibbons SJ; Farrugia G; Taguchi T; Gupta A; Rubin BP; Fletcher JA; Ramachandran A; Ordog T
Gastroenterology; 2015 Aug; 149(2):420-32.e16. PubMed ID: 25865047
[TBL] [Abstract][Full Text] [Related]
6. Mutational profile of KIT and PDGFRA genes in gastrointestinal stromal tumors in Peruvian samples.
Buleje J; Acosta Ó; Guevara-Fujita M; Enriquez Y; Taxa L; Machicado E; Lizaraso-Caparó F; Fujita R
Rev Esp Enferm Dig; 2015 Feb; 107(2):72-8. PubMed ID: 25659388
[TBL] [Abstract][Full Text] [Related]
7. Platelet-derived growth factor receptor family mutations in gastrointestinal stromal tumours.
Sihto H; Franssila K; Tanner M; Vasama-Nolvi C; Sarlomo-Rikala M; Nupponen NN; Joensuu H; Isola J
Scand J Gastroenterol; 2006 Jul; 41(7):805-11. PubMed ID: 16785193
[TBL] [Abstract][Full Text] [Related]
8. Correlation of treatment outcome in sanger/RT‑qPCR
Unk M; Bombač A; Jezeršek Novaković B; Stegel V; Šetrajčič Dragoš V; Blatnik O; Klančar G; Novaković S
Oncol Rep; 2022 Sep; 48(3):. PubMed ID: 35904169
[TBL] [Abstract][Full Text] [Related]
9. Molecular characterization of pediatric gastrointestinal stromal tumors.
Agaram NP; Laquaglia MP; Ustun B; Guo T; Wong GC; Socci ND; Maki RG; DeMatteo RP; Besmer P; Antonescu CR
Clin Cancer Res; 2008 May; 14(10):3204-15. PubMed ID: 18483389
[TBL] [Abstract][Full Text] [Related]
10. [The importance of mutational status in prognosis and therapy of GIST].
Comandone A; Boglione A
Recenti Prog Med; 2015 Jan; 106(1):17-22. PubMed ID: 25621775
[TBL] [Abstract][Full Text] [Related]
11. Gastrointestinal stromal tumors with KIT exon 11 deletions are associated with poor prognosis.
Andersson J; Bümming P; Meis-Kindblom JM; Sihto H; Nupponen N; Joensuu H; Odén A; Gustavsson B; Kindblom LG; Nilsson B
Gastroenterology; 2006 May; 130(6):1573-81. PubMed ID: 16697720
[TBL] [Abstract][Full Text] [Related]
12. A novel fusion between CDC42BPB and ALK in a patient with quadruple wild-type gastrointestinal stromal tumor.
Huang W; Yuan W; Ren L; Xu C; Luo R; Zhou Y; Lu W; Hao Q; Xu M; Hou Y
Mol Genet Genomic Med; 2022 May; 10(5):e1881. PubMed ID: 35319816
[TBL] [Abstract][Full Text] [Related]
13. A Novel Receptor Tyrosine Kinase Switch Promotes Gastrointestinal Stromal Tumor Drug Resistance.
Boichuk S; Galembikova A; Dunaev P; Valeeva E; Shagimardanova E; Gusev O; Khaiboullina S
Molecules; 2017 Dec; 22(12):. PubMed ID: 29206199
[TBL] [Abstract][Full Text] [Related]
14. KIT oncoprotein interactions in gastrointestinal stromal tumors: therapeutic relevance.
Zhu MJ; Ou WB; Fletcher CD; Cohen PS; Demetri GD; Fletcher JA
Oncogene; 2007 Sep; 26(44):6386-95. PubMed ID: 17452978
[TBL] [Abstract][Full Text] [Related]
15. Concomitant KIT/BRAF and PDGFRA/BRAF mutations are rare events in gastrointestinal stromal tumors.
Rossi S; Sbaraglia M; Dell'Orto MC; Gasparotto D; Cacciatore M; Boscato E; Carraro V; Toffolatti L; Gallina G; Niero M; Pilozzi E; Mandolesi A; Sessa F; Sonzogni A; Mancini C; Mazzoleni G; Romeo S; Maestro R; Dei Tos AP
Oncotarget; 2016 May; 7(21):30109-18. PubMed ID: 27097112
[TBL] [Abstract][Full Text] [Related]
16. Pathology of gastrointestinal stromal tumors.
Hirota S; Isozaki K
Pathol Int; 2006 Jan; 56(1):1-9. PubMed ID: 16398673
[TBL] [Abstract][Full Text] [Related]
17. Integrated genomic study of quadruple-WT GIST (KIT/PDGFRA/SDH/RAS pathway wild-type GIST).
Nannini M; Astolfi A; Urbini M; Indio V; Santini D; Heinrich MC; Corless CL; Ceccarelli C; Saponara M; Mandrioli A; Lolli C; Ercolani G; Brandi G; Biasco G; Pantaleo MA
BMC Cancer; 2014 Sep; 14():685. PubMed ID: 25239601
[TBL] [Abstract][Full Text] [Related]
18. Novel V600E BRAF mutations in imatinib-naive and imatinib-resistant gastrointestinal stromal tumors.
Agaram NP; Wong GC; Guo T; Maki RG; Singer S; Dematteo RP; Besmer P; Antonescu CR
Genes Chromosomes Cancer; 2008 Oct; 47(10):853-9. PubMed ID: 18615679
[TBL] [Abstract][Full Text] [Related]
19. The genetic landscape of gastrointestinal stromal tumor lacking KIT and PDGFRA mutations.
Boikos SA; Stratakis CA
Endocrine; 2014 Nov; 47(2):401-8. PubMed ID: 25027296
[TBL] [Abstract][Full Text] [Related]
20. [c-Kit and PDGFRA mutations and clinico-morphological features of gastrointestinal stromal tumors].
Beliakov IS; Anurova OA; Snigur PV; Tsyganova IV; Sel'chuk VIu; Mazurenko NN
Vopr Onkol; 2007; 53(6):677-81. PubMed ID: 18416137
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
